Status:
NOT_YET_RECRUITING
Correlative Analysis Between Magnetic Resonance Spectroscopy (MRS) and Essential Clinicobiological Data in Glioblatoma Multiforme (GBM)
Lead Sponsor:
Centre Hospitalier Universitaire, Amiens
Conditions:
Glioblastoma
MRI Spectroscopy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Glioblastoma multiforme (GBM) is the most common primary brain tumor, and it is well-known to be associated with a poor prognosis. MRI is the key medical technique for the diagnosis and the follow-up ...
Eligibility Criteria
Inclusion
- Patients consecutively identified in the multidisciplinary consultation meeting of neurooncology with a new diagnosis of GBM / a probable diagnosis of GBM. - Patients that have not started radiochemotherapy ;
- Adult \> 18 yrs
- socially-insured,
- having given consent.
Exclusion
- minor patients,
- pregnant/lactating women,
- patients under guardianship,
- curatorship,
- protection of justice or deprived of liberty
Key Trial Info
Start Date :
December 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2029
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT07211841
Start Date
December 1 2025
End Date
April 1 2029
Last Update
November 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Amiens
Amiens, France, 80054